These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38814392)

  • 21. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Potential of mRNA Vaccines to Fight Against Viruses.
    Wang X
    Viral Immunol; 2024 Oct; 37(8):383-391. PubMed ID: 39418074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.
    Spencer AJ; McKay PF; Belij-Rammerstorfer S; Ulaszewska M; Bissett CD; Hu K; Samnuan K; Blakney AK; Wright D; Sharpe HR; Gilbride C; Truby A; Allen ER; Gilbert SC; Shattock RJ; Lambe T
    Nat Commun; 2021 May; 12(1):2893. PubMed ID: 34001897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vaccine development based on RNA technology platforms].
    Guo X; Li J; Wang HM; Qiu J; Li Z; Huang F; Li J; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Aug; 58(8):1263-1277. PubMed ID: 39142899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNA-based HIV-1 vaccines.
    Ahmed S; Herschhorn A
    Clin Microbiol Rev; 2024 Sep; 37(3):e0004124. PubMed ID: 39016564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approaches for vaccine development.
    Gebre MS; Brito LA; Tostanoski LH; Edwards DK; Carfi A; Barouch DH
    Cell; 2021 Mar; 184(6):1589-1603. PubMed ID: 33740454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta.
    Keikha R; Hashemi-Shahri SM; Jebali A
    Sci Rep; 2021 Oct; 11(1):21308. PubMed ID: 34716391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From mRNA sensing to vaccines.
    Fauci AS; Merad M; Swaminathan S; Hur S; Topol E; Fitzgerald K; Reis e Sousa C; Corbett KS; Bauer S
    Immunity; 2021 Dec; 54(12):2676-2680. PubMed ID: 34739870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
    Kutikuppala LVS; Kourampi I; Kanagala RSD; Bhattacharjee P; Boppana SH
    Med Sci (Basel); 2024 May; 12(2):. PubMed ID: 38804384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA vaccines against infectious diseases and future direction.
    Aleem MT; Munir F; Shakoor A; Gao F
    Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA-based vaccines - global approach, challenges, and could be a promising wayout for future pandemics.
    Makhijani S; Elossaily GM; Rojekar S; Ingle RG
    Pharm Dev Technol; 2024 Jul; 29(6):559-565. PubMed ID: 38814266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative Strategies to Enhance mRNA Vaccine Delivery and Effectiveness: Mechanisms and Future Outlook.
    Verma A; Awasthi A
    Curr Pharm Des; 2024; 30(14):1049-1059. PubMed ID: 38551046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omicron: Call for updated vaccines.
    Li X
    J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.
    Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
    Front Immunol; 2021; 12():679344. PubMed ID: 34305909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.